Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive trial data from Onbrez Breezhaler studies

Novartis reports positive trial data from Onbrez Breezhaler studies

16th May 2011

Novartis has published new clinical trial data to further reinforce the safety and efficacy profile of Onbrez Breezhaler in the treatment of chronic obstructive pulmonary disease (COPD).

The company studied the drug in a pair of phase III trials which compared its performance in combination with tiotropium to an alternate therapy of tiotropium alone.

It was found that the combination therapy option provided a significantly greater improvement in lung function among chronic COPD sufferers, meeting the primary endpoint of the studies.

Dr Trevor Mundel, global head of development at Novartis, said the data shows Onbrez Breezhaler "may have even greater therapeutic potential when combined with another leading class of treatment" than it does as a monotherapy.

Novartis is currently seeking US approval for the drug, which has been ratified for sale in Europe since 2009.

Earlier this month, the company announced that its new cancer therapy Afinitor, for which it hopes to receive European authorisation, has won regulatory clearance in the US.ADNFCR-8000103-ID-800534255-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.